The current outbreak of a new strain of E.coli in Germany could see interest grow for PYCs antimicrobial program.
Currently PYC are working with Medimmune(AstraZeneca),scanning PYCs libraries for peptides useful in controling gram negative bacterium, Pseudomonas aeruginosa.PYC also have an inhouse program targeting Acinetobacter baumanii. Both are superbugs responsible for significant numbers of hospital-based infections.
AstraZeneca are one of only a few pharmas with solid R&D into the Antimicrobial,Antibacterial,Antibiotic field.
The following link is a Reuters article on the outbreak.
Cheers ST
http://www.guardian.co.uk/uk/2011/may/30/ecoli-outbreak-death-toll
The current outbreak of a new strain of E.coli in Germany could...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |